AID Life Science Holdings Limited provided group earnings guidance for the nine months ended September 30, 2018. the Group is expected to record a significant decrease in loss for the nine months ended 30 September 2018, as compared to that for the nine months ended 30 September 2017, which was mainly attributable to loss on reclassification of interest in an associate to an investment for the nine months ended 30 September 2017, whereas no such loss was recognised for the Period; and unrealised fair value gain recognised as a result of fair value change of a financial asset at fair value through profit or loss during the Period (such loss or gain are non-cash in nature and will not have any cash flow impact to the Group).